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Background: Individuals with Fetal Alcohol Spectrum Disorder (FASD) constitute a special population that may be
at particularly high risk for substance use. The purpose of the current study was to estimate the utilization of
specialized addiction treatment services (SATS) and the associated cost, as a part of the total cost of health care
associated with FASD in Canada.
Methods: The current study was a modeling study. Data on SATS by lifetime mental disorder status were obtained
from the Drug and Alcohol Treatment Information System (DATIS) in Ontario, Canada for 2010/11. The number of
clients with FASD who received SATS in Ontario in 2010/11 was estimated, assuming that approximately 37%
(confidence interval: 21.6%-54.5%) of individuals with FASD abuse or are addicted to alcohol and/or drugs and that
their utilization rate of SATS is the same as those for people with a lifetime mental disorder. The data from DATIS
was then extrapolated to the total Canadian population.
Results: The cost of SATS for clients with FASD in Canada in 2010/11 ranged from $1.65 million Canadian dollars
(CND) to $3.59 million CND, based on 5,526 outpatient visits and 9,529 resident days. When the sensitivity analysis
was performed the cost of SATS ranged from $979 thousand CND to $5.34 million CND.
Conclusions: Special attention must be paid to at-risk groups of individuals such as those with FASD, in order to
reduce the likelihood of the development of co-morbid substance abuse problems, and thus, reducing the overall
burden on Canadian society.
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This study is a part of a large economic study on the es-
timation of the burden and cost associated with Fetal Alco-
hol Spectrum Disorder (FASD) in Canada [1,2]. FASD is a
non-diagnostic term that encompasses four alcohol-related
clinical diagnoses, including: Fetal Alcohol Syndrome
(FAS), Partial FAS, Alcohol-Related Neurodevelopmental
Disorder, and Alcohol-Related Birth Defects.
Individuals with FASD have an increased vulnerability
to certain risk factors, which put them at a higher risk
for substance use/abuse problems, as a result of the
damage caused to their central nervous system due to* Correspondence: lana.popova@camh.ca
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reproduction in any medium, provided the ortheir exposure to alcohol prenatally. This damage mani-
fests as developmental delays, cognitive impairments,
mental disorders, high rates of incarceration and an in-
creased rate of substance abuse [3-5].
The impairments expressed by individuals with FASD
typically lead to high-risk behaviours, such as alcohol/
drug abuse or an increased likelihood of being in high-
risk situations (increasing the chance of being exposed
to alcohol and/or drugs). Currently, there are not ma-
ny epidemiological studies reporting on the prevalence
of substance use/abuse among individuals with FASD.
However, the literature does indicate that a dispropor-
tionate number of individuals with FASD will have prob-
lematic substance use issues at some point in their lives
[6]. For instance, Famy et al. [7] reported a prevalence of
55% for alcohol/drug dependence among their sample of
individuals with FAS. Additionally, Clark and colleaguesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and 35% of their respective cohorts of individuals with
FASD had problems with alcohol/drugs. Lastly, in a
study conducted by Grant and colleagues [10], about
68% of women with FASD had reported abusing alcohol
and 79% had used illegal drugs in the 10 months prior
to being admitted into a community program.
There are a few potential explanations for the high
prevalence of substance use among individuals with
FASD: 1) a biological vulnerability to substance use
may exist; 2) individuals with FASD may use substances
to self-medicate; and 3) individuals with FASD tend to
have difficulties with impulse control, making them
susceptible to developing a substance use disorder [11].
Regardless of the reason for such high rates of co-
occurring substance use problems and FASD, this
population places a greater demand on treatment ser-
vice providers, given that they suffer from multiple co-
morbid mental disorders [8,12,13].
Prenatal alcohol use exposes three generations to the
harmful effects of alcohol (the mother, the fetus, and the
germ line of the fetus). Increased rates of substance
abuse increase the risk for additional familial cases of
FASD (multiple affected siblings), and increase the risk
of generational FASD [3,14]. Therefore, it is also import-
ant to address the issue of women of childbearing age
with FASD so that the generational effects of FASD can
be halted.
In Canada, as is common elsewhere, specialized addic-
tion treatment services provide a continuum of care,
from assistance with symptoms of withdrawal through
to active treatment and continuing care [15]. They vary,
however, in their capacity for assisting clients with co-
occurring disorders [15,16], which would include com-
plications arising from FASD among others. Prior re-
search suggests that people with co-morbid substance
use and mental disorders have a more complicated tra-
jectory of service use, including higher rates of relapse
and readmission to addiction treatment [17-22]. Given
the high-risk nature of FASD for multiple health and so-
cial comorbidities, it is of interest to understand their
representation in the specialized addiction treatment
system.
The purpose of this study was to estimate the use of
specialized addiction treatment services and the asso-
ciated cost, as a part of the total cost of health care asso-
ciated with FASD in Canada.
Methods
Since there is great uncertainty regarding the true preva-
lence of people with FASD in the general population,
and the prevalence of people with FASD who abuse or
are addicted to substances, specifically, in combina-
tion with the lack of FASD-specific data pertaining tospecialized addiction treatment services in Canada,
several important assumptions were used and sensitiv-
ity analyses were conducted, as described step-by-step
below.
Source of data
Data were obtained from the Drug and Alcohol Treat-
ment Information System (DATIS; www.datis.ca), which
monitors the use of specialized addiction treatment ser-
vices by people in Ontario, Canada. Started in 1992,
DATIS collects data on the numbers and types of clients
entering publicly funded specialized addiction treatment
across the province. This system includes approximately
200 treatment programs, administered by 170 agencies
[23,24]. The types of services provided by each agency
can vary; some agencies provide a specific type of service
(e.g., assessment and referral, withdrawal management,
individual counseling), while others provide a compre-
hensive mix of services. Regardless of the type of service,
all services are delivered free-of-charge to Ontario resi-
dents (i.e., they are covered by the province’s universal
health insurance plan). Agency-level participation has
been over 95% since 2000.
The DATIS database is structured by admissions to
treatment programs, such that a new admission is trig-
gered when a client enters a new treatment program or
transitions between two different types of services. Since
2002, data entry has been supported by a web-based user
platform accessible by all frontline clinicians working
in the designated programs across the province. Data
entry fields correspond to 66 data elements that are
mandatory for all admissions. Sociodemographic cha-
racteristics, information on substance use, and other
treatment-related factors (e.g., referral source, current
and past diagnoses of mental disorders, and treatment
mandates) are entered by the service provider at admis-
sion, typically following the first face-to-face encounter
with the client. Unique identifiers for individual clients
and agencies are generated automatically by the soft-
ware, as is a variable documenting the type of treatment
program or service (i.e., outpatient, residential or resi-
dential withdrawal management). Details on service use,
including the number of outpatient visits and days or
residential care, are entered by service providers at dis-
charge. Data are stored on a central server located at the
Centre for Addiction and Mental Health in Toronto,
Canada.
Study population
All admissions corresponding to services received during
the 2010/11 fiscal year (April 1, 2010 to March 31, 2011;
N=91,333) were extracted for analysis. This included all
admissions occurring during the fiscal year, as well as
those where treatment had started prior to April 1,
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noted above, an admission corresponds to a particular
type of service, with movement between types of services
(e.g., from a residential service to an outpatient pro-
gram) counted as separate admissions. Multiple admis-
sions per individual client were included. This was done
to ensure that the most complete estimates of the vol-
ume and costs of services delivered during the study
period were obtained. Therefore, it is important to note
that each admission does not necessarily represent a
separate individual, as one individual can have multiple
admissions.Data elements
In order to determine whether or not a client has had a
“lifetime mental disorder” (i.e., a diagnosed mental dis-
order at any point within their lifetime; response: yes
versus no), the question “Have you ever been diagnosed
by a qualified mental health professional with a mental
disorder within the last 12 months or within your life-
time?” was asked to each client at the beginning of
treatment.
Age groups, divided into 5-year intervals from 14 years
of age and younger to 70 years of age and older, were
generated from the clients’ date of birth. All variables
(lifetime mental disorder, date of birth, and sex) were
self-reported by the clients during their initial clinical
encounter.
Service type (i.e., outpatient, residential treatment, or
residential withdrawal management, automatically gen-
erated in DATIS) was abstracted, as were the number of
visits for outpatient treatment and days in residential
treatment and residential withdrawal management. The
numbers of visits and days of care, entered by service
providers based on client charts, provide estimates of
the volume of services received. For admissions that
began prior to or ended after the 2010/11 fiscal year,
only those visits/days that occurred within the study
period were counted. To comply with Personal Health
Information Protection Act (2004), cells with values less
than 6 were redacted and replaced with "<6".Estimation of the prevalence of clients with FASD in
specialized addiction treatment and their utilization of
these services
Number of people with FASD in Canada
The prevalence of FAS and FASD are currently un-
known in Canada. However, the most commonly cited
rough estimates are 1 per 1,000 for FAS [25], and 9 per
1,000 for FASD [26]. Using data on the general popula-
tion, by age group and sex, of Canada in 2010 [27], and
assuming a prevalence of 9 per 1,000 for FASD [26], the
number of people with FASD in Canada was estimated.Number of people with FASD who abuse or are addicted
to alcohol and/or drugs
In order to estimate the number of clients with FASD
who had received specialized addiction treatment ser-
vices in Canada in 2010/11, the prevalence of individuals
with FASD who abuse or are addicted to alcohol and/or
drugs was calculated based on available epidemiological
studies [7-10] using the meta-analysis technique de-
scribed below.Meta-analysis
Prevalence data from the epidemiological studies
concerning alcohol/drug abuse/use/dependence among
those with FASD were transformed into log-odds for the
meta-analysis [28]. Log-odds estimates were weighted by
the inverse variance of the log-odds transformed preva-
lence. Heterogeneity between studies was assessed using
the Cochrane Q-test and the I2 statistic [29,30]. The pre-
valence estimates were pooled using the Mantel-Haenszel
method, using a random-effects model [31].
Publication bias was tested by: 1) visually inspecting a
funnel plot for skewed distribution, 2) using a ranked
correlation test [32], and 3) employing a weighted re-
gression test [33]. Publication bias was then adjusted for
using the trim and fill method [34].Number of people with FASD who utilized specialized
addiction treatment services and their rate of utilization
in 2010/11
In order to calculate the number of people with FASD
who utilized specialized addiction treatment services in
2010/11, it was assumed that the rate of specialized
addiction treatment services among this population
(individuals with FASD) was the same as the rate among
individuals with a lifetime mental disorder. This assump-
tion is based on a very high prevalence of co-morbid
mental illness reported among individuals with FASD
[7,9,35,36]. Based on the authors’ comprehensive litera-
ture review (Popova et al., unpublished), the weighted
mean for mental retardation (International Classification
of Diseases, version 10 [ICD-10] category: F70-F79)
among individuals with FASD is 48% (95% confidential
interval [CI]: 44.4%-51.4%) and for disorders of psycho-
logical development (ICD-10 category: F80-F89) is 37%
(95% CI: 35.9%-39.0%).
In order to estimate the rate of utilization of specia-
lized addiction treatment services for individuals with a
lifetime mental disorder, the number of specialized ad-
diction treatment services admissions for individuals
with a lifetime mental disorder was divided by the total
number of individuals with a mental illness in Ontario
(reported by the Ministry of Health and Long-Term
Care [36] and Health Canada [37]).
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admissions, and visits/days, by treatment type, among
clients with FASD for all of Canada, the distribution for
each treatment type among clients who received spe-
cialized addiction treatment services in the province of
Ontario was used and extrapolated to the total Canadian
population. This approach is justifiable given that
Ontario represents about 39% of the total population
of Canada.Estimation of costs
The cost for specialized outpatient treatment ranged
from $60 to $109 per service and for residential treat-
ment ranged from $138 to $314 per resident day in
Canada in 2010/11 (Martin et al., in progress). These
unit costs are estimated based on the costs reported
by five Local Health Integration Networks (LHINs)
across Ontario. The overall estimates are inclusive of
the cost of supervision, facility costs, salaries, and
other sundry expenses. The ranges reported account
for the differences in costs incurred due to the num-
ber of spots/beds available (capacity), whether the
treatment is hospital based or community based, the
intensity of activities provided, and staff professionalismTable 1 Estimated number of admissions, visits and cost of o




15-19 20-24 25-29 30-34 35-39 40-44 45-49
Clients with FASD in Ontario
Number of admissions
Male <6 15 13 11 12 11 13 13
Female <6 10 11 13 13 12 11 12
Total <6 25 24 24 25 23 24 25
Number of visits
Male 17 98 91 93 124 124 143 137
Female 23 82 106 143 127 121 127 147
Total 40 180 197 237 250 245 270 283
Clients with FASD in Canada
Number of admissions
Male 6 38 32 29 31 29 34 33
Female <6 26 30 34 32 30 28 31
Total 10 63 62 63 64 59 61 64
Number of visits
Male 43 251 236 241 319 320 369 353
Female 59 212 272 370 326 312 327 378
Total 102 463 508 610 645 632 696 731
FASD: Fetal Alcohol Spectrum Disorder.
Note. Cells with values less than 6 were redacted and replaced with "<6".(which affects both their salaries and the scope of the staff
complement).
The corresponding costs - for outpatient treatment:
$60 and $109 per service as the lower and upper esti-
mates, respectively; and for residential treatment: $138
and $314 per resident day as the lower and upper
estimates, respectively - were applied to substance-
attributable specialized outpatient visits and residential
days, in order to obtain the total costs of such services
for clients with FASD.
All cost figures are presented in Canadian dollars.Sensitivity analysis
Due to a very limited number of existing epidemiological
studies, there is great uncertainty regarding the pre-
valence of individuals with FASD who abuse or are
addicted to alcohol and/or drugs. As described above,
the weighted mean of 37% (CI: 21.6%-54.5%), which was
calculated based on the available epidemiological studies
[7-10] was used in the main analysis. In addition, two
separate analyses were performed assuming that 22% (as
the lower estimate) and 55% (as the upper estimate; both
are based on the estimated CI) of individuals with FASD
abuse or are addicted to alcohol and/or drugs.utpatient treatment services among clients with FASD by
Cost








10 7 <6 <6 <6 112
8 <6 <6 <6 <6 99
18 11 6 <6 <6 212
111 90 29 14 7 1,078 $64,670 $117,484
79 56 31 15 9 1,065 $63,914 $116,111
190 146 60 29 16 2,143 $128,585 $233,595
26 18 8 <6 <6 290
20 12 6 <6 <6 256
46 29 14 6 <6 546
286 232 75 37 18 2,779 $166,759 $302,946
204 145 81 38 22 2,747 $164,810 $299,405
490 377 156 74 40 5,526 $331,569 $602,350
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Calculation of the rate of specialized addiction
treatment service among individuals with a lifetime
mental disorder
Given that 20% of the population, age 12 and over, of
Ontario [37] reported a mental health diagnosis such as
mood disorders, anxiety disorders, and/or schizophrenia
in 2005 and based on the population size of Ontario
(13,227,791 [27]), the total number of individuals who
suffer with a mental illness in Ontario was calculated to
be 2,645,558. The rate of 20% has also been reported for
all of Canada [38].
In order to estimate the rate of utilization of spe-
cialized addiction treatment services for individuals
with a lifetime mental disorder, the number of spe-
cialized addiction treatment services admissions for
clients with a lifetime mental disorder (N=37,164;
obtained from DATIS for 2010/11) was divided by
the total number of individuals with a mental illness
in Ontario (2,645,558), resulting in the rate of 1.4%.
The rate of utilization of specialized addiction treat-
ment services for individuals without a lifetime men-
tal disorder was estimated to be almost three times
lower (i.e., 0.5%).Table 2 Estimated number of admissions, resident days and c




15-19 20-24 25-29 30-34 35-39 40-44 45-49 5
Clients with FASD in Ontario
Number of admissions
Male <6 <6 <6 <6 6 7 6 6 5
Female <6 <6 <6 <6 <6 <6 <6 <6 <
Total <6 <6 8 11 10 10 9 10 7
Number of days
Male <6 99 158 200 234 264 235 292 2
Female <6 84 104 174 143 116 114 102 9
Total 7 183 262 374 376 381 349 394 3
Clients with FASD in Canada
Number of admissions
Male <6 6 11 14 15 17 14 16 1
Female <6 <6 10 13 10 9 9 9 <
Total <6 10 21 27 25 25 23 25 1
Number of days
Male 13 254 407 515 603 682 607 753 5
Female <6 217 267 450 368 300 294 263 2
Total 18 471 675 965 971 982 900 1,016 8
FASD: Fetal Alcohol Spectrum Disorder.
Note. Cells with values less than 6 were redacted and replaced with "<6".Estimation of the number of clients with FASD who
received specialized addiction treatment services in
Ontario and Canada in 2010/11
Using data on the general population of Ontario in 2010
(13,227,791 [27]) and assuming a prevalence of 9 per
1,000 for FASD [26], it was estimated that there were
119,050 individuals with FASD in Ontario in 2010/11.
Results of the meta-analysis revealed that appro-
ximately 37% of individuals with FASD abuse or are
addicted to alcohol and/or drugs. Applying 37% to
119,050 individuals with FASD, results in 44,049 of indi-
viduals with FASD who abuse or are addicted to alcohol
and/or drugs in Ontario in 2010/11. Assuming that the
utilization rate of specialized addiction treatment ser-
vices among individuals with FASD is the same as those
for people with a lifetime mental disorder (1.4%; see
above), the number of admissions for clients with FASD
who received specialized addiction treatment services in
Ontario in 2010/11 was estimated to be 617.
Similarly, using data on the general population of
Canada in 2010 (34,126,181 [27]) and an assumed preva-
lence of 9 per 1,000 for FASD [26], it was estimated that
there were 307,136 individuals with FASD in Canada in
2010/11.ost of residential treatment services among clients with
Cost








<6 <6 <6 <6 44
6 <6 <6 <6 <6 29
<6 <6 <6 <6 73
23 93 41 9 7 1,855 $256,056 $582,621
0 49 10 <6 <6 989 $136,472 $310,524
13 142 51 12 7 2,844 $392,529 $893,145
3 6 <6 <6 <6 115
6 <6 <6 <6 <6 74
8 9 <6 <6 <6 189
76 241 105 24 18 4,785 $660,269 $1,502,351
31 126 27 6 <6 2,550 $351,908 $800,718
07 367 131 30 19 7,335 $1,012,177 $2,303,069
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(113,640) of individuals with FASD abuse or are addicted
to alcohol and/or drugs and that the utilization rate of
specialized addiction treatment services among individ-
uals with FASD is the same as those for people with a
lifetime mental disorder (1.4%; see above), the number
of admissions for clients with FASD who received spe-
cialized addiction treatment services in Canada in 2010/
11 was estimated to be 1,591.Service utilization and estimation of the cost associated
with addiction treatment services for clients with FASD
Based on the service rates obtained from DATIS, and
the assumption that individuals with FASD have the
same utilization rates as those of individuals with a life-
time mental disorder, it was estimated that there were
1,591 admissions in total in Canada (546 for outpatient,
189 for residential, and 856 for withdrawal management)
among clients with FASD. These admissions resulted in
5,526 outpatient visits, and 9,529 residential days; the as-
sociated cost was estimated to range from $1.65 million
to $3.59 million.
The number of admissions, visits/days in out-
patient treatment, residential treatment, and residentialTable 3 Estimated number of admissions, resident days and c




15-19 20-24 25-29 30-34 35-39 40-44 45-49
Clients with FASD in Ontario
Number of admissions
Male <6 7 19 29 31 28 31 30
Female <6 <6 15 18 16 13 14 13
Total <6 12 34 47 48 42 45 43
Number of days
Male <6 20 41 61 70 83 90 88
Female <6 10 35 36 40 28 36 28
Total <6 30 76 97 110 111 126 117
Clients with FASD in Canada
Number of admissions
Male <6 18 49 74 81 73 81 77
Female <6 14 37 47 42 35 36 32
Total <6 32 87 121 123 107 117 110
Number of days
Male <6 51 105 157 180 214 232 228
Female <6 26 91 94 104 73 94 73
Total <6 77 196 251 285 286 325 301
FASD: Fetal Alcohol Spectrum Disorder.
Note. Cells with values less than 6 were redacted and replaced with "<6".withdrawal management services and costs among cli-
ents with FASD by age groups and sex in Ontario
and Canada in 2010/11 are presented in Tables 1, 2,
and 3, respectively.
The total number of admissions, visits/days and costs
of specialized addiction treatment services among clients
with FASD for Ontario and Canada, as a whole, in 2010/
11 are presented in Table 4 and Figures 1, 2 and 3
(FAS is figuratively presented separately).
Please note that the number of admissions, visits/days
and costs of specialized addiction treatment services by
province/territory among clients with FASD in 2010/11
are available from the authors upon request.
On average, in Canada, there were per admission ap-
proximately 10 visits for outpatient treatment; 39 days
for residential treatment; and 3 days for residential with-
drawal management services.
Further, it was estimated that in Canada in 2010/11
there were approximately 445 specialized addiction
treatment services admissions of women of childbear-
ing age (15–44) with FASD (Figure 4). These admis-
sions resulted in 1,819 outpatient visits and 2,378
residential days (1,896 days in residential treatment,
and 482 days in residential withdrawal treatment;
Figure 5).ost of residential withdrawal management services
Canada in 2010/11
Cost








24 14 <6 <6 <6 219
10 <6 <6 <6 <6 111
33 19 6 <6 <6 332
75 30 23 <6 <6 587 $80,941 $184,169
29 13 <6 <6 <6 264 $36,455 $82,948
104 43 28 <6 <6 851 $117,438 $267,213
61 37 12 <6 <6 566
25 12 <6 <6 <6 287
86 49 16 <6 <6 856
194 78 60 8 7 1,512 $208,714 $474,901
74 33 12 <6 <6 681 $94,003 $213,891
268 111 72 12 9 2,194 $302,825 $689,037
Table 4 Estimated number of admissions, outpatient visits, resident days and costs of specialized addiction treatment
services among clients with FASD in Ontario, and Canada in 2010/11
Number of admissions, outpatient
visits and resident days; associated





with FASD (based on a
prevalence of 9 per 1,000)
Types of specialized addiction treatment
services
Outpatient Residential Withdrawal Overall
Ontario 13,227,791 119,050
Number of admissions 212 73 332 617
Number of visits 2,143 2,143
Number of days 2,844 851 3,695
Cost (Lower estimate) $128,585 $392,529 $117,438 $638,551
Cost (Upper estimate) $233,595 $893,145 $267,213 $1,393,953
Canada (All provinces/territories) 34,126,181 307,136
Number of admissions 546 189 856 1,591
Number of visits 5,526 5,526
Number of days 7,335 2,194 9,529
Cost (Lower estimate) $331,569 $1,012,177 $302,825 $1,646,571
Cost (Upper estimate) $602,350 $2,303,069 $689,037 $3,594,456
1) Sensitivity analysis, assuming 22%
(lower estimate) of individuals with
FASD suffer from addiction
34,126,181 307,136
Number of admissions 325 112 509 946
Number of visits 3,286 3,286
Number of days 4,361 1,305 5,666
Cost (Lower estimate) $197,144 $601,866 $180,029 $979,037
Cost (Upper estimate) $358,145 $1,369,464 $409,626 $2,137,235
2) Sensitivity analysis, assuming 55%
(upper estimate) of individuals with
FASD suffer from addiction
34,126,181 307,136
Number of admissions 812 281 1,272 2,365
Number of visits 8,214 8,214
Number of days 10,903 3,261 14,165
Cost (Lower estimate) $492,859 $1,504,666 $450,066 $2,447,592
Cost (Upper estimate) $895,361 $3,423,661 $1,024,064 $5,343,086
a Source: Statistics Canada [23].
FASD: Fetal Alcohol Spectrum Disorder.
Note. Columns may not add up due to rounding errors.
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Assuming that 22% (as the lower estimate) of individuals
with FASD abuse or are addicted to alcohol and/or
drugs, it was estimated that there were 946 admissions
in total (325 for outpatient, 112 for residential, and 509
for withdrawal management) in Canada in 2010/11 -
resulting in 3,286 outpatient visits and 5,666 resident
days. The associated cost was estimated to range from
$979 thousand to $2.14 million (Table 4).
Assuming that 55% (as the upper estimate) of individ-
uals with FASD abuse or are addicted to alcohol and/or
drugs, it was estimated that there were 2,365 admissions
in total (812 for outpatient, 281 for residential, and 1,272
for withdrawal management) in Canada in 2010/11. Theseadmissions resulted in 8,214 outpatient visits and 14,165
resident days. The associated cost was estimated to range
from $2.45 million to $5.34 million (see Table 4).
Discussion
It is clear from the current estimated costs associated
with specialized addiction treatment services for cli-
ents with FASD in Canada that substance abuse
problems among this specific population place an add-
itional economic burden on Canadian society. It is im-
portant to note that the cost of specialized addiction
treatment services, estimated in the current study, is
only a part of the total cost of health care associated
with FASD [1,2,39,40].
Legend 
Fetal Alcohol Syndrome (FAS)
Fetal Alcohol Spectrum Disorder (FASD)
Figure 3 The overall estimated costs associated with
specialized addiction treatment among clients with FASD
(including FASa) in Canada 2010/11. LE: Lower Estimate. UE: Upper
Estimate. a Estimated based on a prevalence of 1 per 1,000 [21].
Legend 
Fetal Alcohol Syndrome (FAS)
Fetal Alcohol Spectrum Disorder (FASD)
Figure 1 Estimated number of admissions among clients with
FASD (including FASa) in Canada 2010/11. a Estimated based on
a prevalence of 1 per 1,000 [21].
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mental disorder represent a large portion of those utiliz-
ing specialized addiction treatment services in Canada –
about 40%. This has also been supported by previous
research [41-43]. Within this group are those with FASD,
which represent a population that is high-risk for con-
current mental health disorders [7,12,13,44,45]. Research
shows that such high-risk populations with co-morbid
mental disorders have higher rates of relapse and read-
mission to treatment, and thus, have a more complicated
trajectory of service use and place a greater demand on
service providers [17-22].
Individuals with FASD who abuse substances consti-
tute a special population for service providers forLegend 
Fetal Alcohol Syndrome (FAS)
Fetal Alcohol Spectrum Disorder (FASD)
Figure 2 Estimated number of visits/inpatient days among clients
with FASD (including FASa) in Canada 2010/11. a Estimated based
on a prevalence of 1 per 1,000 [21].multiple reasons. First, all individuals with FASD have
an affected family member and many will have multiple
affected family members [14,46,47]. Second, nearly all
individuals with FASD have neurocognitive impairments
that will affect their response to substance abuse treat-
ment [12]. Third, many, if not most individuals with
FASD entering substance abuse treatment will not be
recognized as having FASD. This is especially true in the
correctional system [48,49]. Fourth, very few substance
abuse treatment programs have the needed adaptations
for clients with FASD. This gap in services may increase
their risk of treatment failure and/or relapse. Fifth, treat-
ment strategies of women with FASD should be different
from those for men [50]. An essential goal for women
with FASD must be to increase their knowledge of the
effects of prenatal alcohol exposure and a treatment goal
must be no use of alcohol after their child bearing years.
This is crucial since no known level of alcohol useFigure 4 Estimated number of admissions among female
clients of childbearing age with FASD in Canada 2010/11.
Figure 5 Estimated number of visits/inpatient days among
female clients of childbearing age with FASD in
Canada 2010/11.
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some interventions focus on birth control, it is also im-
portant to acknowledge that this intervention is not
100% effective, and that some women will not adhere to
treatment protocols. In the current study, it was esti-
mated that each month women of childbearing age are
responsible for about 18 admissions in withdrawal man-
agement programs in Canada.
There are several limitations of the current study that
are worth mentioning. First, the prevalence of FASD is
unknown in Canada; therefore, for the purpose of this
analysis, the most commonly cited rough estimate of the
prevalence of FASD (9 per 1,000 [26]) was used, which
may not be accurate. Second, the utilization rate of spe-
cialized addiction treatment services by individuals with
FASD is unknown in Canada; therefore, it was assumed
that their utilization rate is the same as those for people
with a lifetime mental disorder. Third, the number of
individuals with a lifetime mental disorder may be un-
derestimated in the current study due to at least two
reasons: 1) self-reported data is a subject to recall bias;
and 2) by asking clients to self-report mental diagnoses,
those who have not previously sought services or have
not received a diagnosis were excluded. As such, using
the assumption that the utilization rate of specialized ad-
diction treatment services among individuals with FASD
is the same as that of people with a lifetime mental ill-
ness, it is likely that the utilization rate of individuals
with FASD is also underestimated in the current study.
The data presented here on the number of women of
childbearing age (15 to 44 years) with FASD in sub-
stance abuse treatment (approximately 450 admissions)
highlights the increased risk for additional FASD cases
among the future children of these women. Based on
these data, there is an evident need for additional training
for programs serving this population. System-wide scree-
ning strategies and targeted interventions for women of
childbearing age with FASD also need to be developed.These recommendations should be primary prevention
priorities for substance abuse prevention programs.Conclusions
Special attention must be paid to at-risk groups of indi-
viduals – such as those with FASD, in order to reduce
the likelihood of the development of secondary disabi-
lities (in this case, substance abuse problems). Reducing
the occurrence of substance abuse problems will allevi-
ate a portion of the costs being allocated to specialized
addiction treatment services in Canada, and thus, will
reduce the overall burden on Canadian society.
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